'Merck Keeps Kinase Inhibitor Options Open As It Partners With Exelixis To Test Zanzalintinib Alongside Welireg In Renal Cancer; Collaboration Raises Questions About Merck's Ongoing Renal Trials With Lenvima, Litespark-011 Trial Completion Is Delayed To 2026; Companies To Co-Fund Phase 1/2 Trial With Merck Sponsoring Two Phase 3 Studies; Merck To Supply Keytruda For Exelixis-Sponsored Head And Neck Cancer Trial' - Oncology Pipeline

Benzinga · 10/15 15:09